VST places No. 58 overall with 497% three-year revenue growth; portfolio spans

The 497% increase represents nearly a sixfold expansion in revenue over the measurement period. The recognition comes as
"Behind this recognition are years of building, teams that kept executing and shareholders who supported us along the way," said
Continued growth beyond the ranking period
The ranking measures revenue growth through 2025.
- Consolidated revenue of
$53.0 million , compared with$9.9 million in the first half of 2025, an increase of approximately 434%. - Consolidated gross profit of
$10.5 million , compared with$3.4 million in the corresponding period. - Consolidated cash of
$20.2 million and working capital of$34.5 million as atJune 30, 2026 .
First-half consolidated revenue growth was primarily attributable to
| All financial amounts are in Canadian dollars. Readers should review the Company's financial statements and Management's Discussion and Analysis on SEDAR+ for additional information. |
What investors gain exposure to through VST
Current areas of focus include:
Hydreight (TSXV: NURS) operates a digital health infrastructure platform supporting healthcare providers, businesses and direct-to-consumer healthcare brands across all 50 U.S. states. Its platform brings together technology, physician coverage, pharmacy relationships and compliance infrastructure. Hydreight is the principal driver of
Insu Therapeutics — Peptide drug delivery
Insu is developing technology designed to deliver peptide-based medicines through the inner cheek, known as buccal delivery. Its research includes evaluating the delivery of existing therapies such as semaglutide through an alternative route of administration. Insu remains a development-stage biotechnology business; clinical validation and applicable regulatory approvals are required before commercialization.
Pawsible is a pet-health venture platform supporting founders across veterinary technology and animal wellness. In
These businesses represent different stages of development. Hydreight provides established commercial operations, while Insu and Pawsible offer exposure to earlier-stage opportunities with distinct development and execution risks.
"Our model gives investors a way to participate in businesses they might otherwise encounter only through private markets," added Tejani. "We work alongside founders and management teams to help those businesses move forward. Our priorities are to support execution, allocate capital carefully and translate portfolio progress into long-term value for VST shareholders."
Meet the portfolio:
The webinar will include a closer look at Hydreight,
The event will include a live shareholder Q&A.
On behalf of the Board of Directors
Chairman & Chief Executive Officer
About
The 2026 ranking is available in the October issue of Report on
About Victory Square Technologies Inc.
Victory Square builds, acquires and invests in technology companies, providing capital, strategic leadership and operational support to help them develop and scale. Its portfolio includes operating and development-stage businesses across healthcare infrastructure, digital health, artificial intelligence, pet health and other emerging technology sectors.
Headquartered in Vancouver, Canada, Victory Square trades on the Canadian Securities Exchange, the OTCQX market and the Frankfurt Stock Exchange.
For more information, visit www.victorysquare.com.
Forward-Looking Information
This news release contains forward-looking information within the meaning of applicable securities laws, including statements concerning Victory Square's business strategy, portfolio development, capital allocation, potential shareholder value, Insu Therapeutics' drug-delivery technology and potential commercialization, Pawsible Ventures' development opportunities, and the timing and content of the planned investor webinar.
Such information is based on management's current expectations and assumptions, including the availability of capital, demand for portfolio companies' products and services, successful research and development, receipt of applicable regulatory approvals and the ability to execute business plans. Actual results may differ materially due to risks including market and economic conditions, financing requirements, competition, regulatory changes, clinical and technological uncertainty, and operational execution. Additional risks are described in the Company's public filings on SEDAR+.
Historical revenue growth and inclusion in an editorial ranking do not guarantee future operating results or investment returns. Readers should not place undue reliance on forward-looking information. The Company undertakes no obligation to update such information except as required by applicable law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/victory-square-technologies-ranks-no-2-among-publicly-traded-companies-on-the-globe-and-mails-2026-canadas-top-growing-companies-list-302899250.html
SOURCE Victory Square Technologies Inc